Aspen Sells Ovestin Rights for 197 Million Euros
South Africa's Aspen Pharmacare agreed to sell European commercialisation rights for its Ovestin product to Ennogen Healthcare for €197 million. Aspen will continue manufacturing the treatment for at least a decade under long-term supply agreements.
Xurve View
Insights:
Xurve View
Aspen Pharmacare Holdings Ltd will sell European commercialisation rights for its women's health product Ovestin to Ennogen Healthcare International for €197 million ($220 million). The transaction includes related inventory valued at €4 million. The deal allows South Africa-based Aspen to refocus its operations on emerging markets.
